Takeda Pharmaceutical (NYSE:TAK) Sets New 52-Week High – Still a Buy?

Takeda Pharmaceutical Co. (NYSE:TAK)’s stock price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $15.69 and last traded at $15.59, with a volume of 561228 shares changing hands. The stock had previously closed at $15.40.

Wall Street Analyst Weigh In

Separately, Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.1%

The stock has a market cap of $48.62 billion, a price-to-earnings ratio of 50.93 and a beta of 0.22. The business’s fifty day simple moving average is $14.82 and its 200 day simple moving average is $14.81. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. On average, research analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Institutional Investors Weigh In On Takeda Pharmaceutical

A number of hedge funds have recently added to or reduced their stakes in TAK. Dimensional Fund Advisors LP lifted its stake in Takeda Pharmaceutical by 60.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company’s stock valued at $2,409,000 after buying an additional 68,200 shares during the last quarter. Jane Street Group LLC raised its stake in shares of Takeda Pharmaceutical by 109.0% during the fourth quarter. Jane Street Group LLC now owns 254,647 shares of the company’s stock valued at $3,372,000 after purchasing an additional 132,817 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Takeda Pharmaceutical by 15,449.0% during the fourth quarter. BNP Paribas Financial Markets now owns 500,677 shares of the company’s stock valued at $6,629,000 after purchasing an additional 497,457 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Takeda Pharmaceutical during the fourth quarter valued at about $2,558,000. Finally, Cetera Investment Advisers raised its stake in shares of Takeda Pharmaceutical by 14.7% during the fourth quarter. Cetera Investment Advisers now owns 59,273 shares of the company’s stock valued at $785,000 after purchasing an additional 7,574 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.